BioMS Medical announces 17 additional patents for MS drug

24-Mar-2004
BioMS Medical Corp, a leading´developer in the treatment of multiple sclerosis (MS), announced that the University of Alberta has received seventeen additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical, through a subsidiary, licenses these patents on an exclusive worldwide basis from the University of Alberta. The additional countries granting patents included Austria, Belgium, the Czech Republic, Denmark, Finland, France, Greece, Germany, Ireland, Luxembourg, Monaco, Netherlands, Spain, Sweden, Switzerland, Ukraine and the United Kingdom. In total, 50 patents have been granted to the University of Alberta for MBP8298 in 29 countries worldwide, including three patents issued in the United States. "We continue to build a very powerful intellectual property portfolio for our lead product, MBP8298," said Kevin Giese, President of BioMS Medical. "With patent protection in the United States, Canada and many of the key European countries where MS is highly present, the future commercial value of our MS drug is well protected."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances